文献速递艾滋病与性传播感染

全国队列研究:2011-2015年中国抗逆转录病毒治疗时机与治疗脱失及病毒学失败

Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011-2015.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该全国队列纳入2011年1月1日至2014年12月31日启动抗逆转录病毒治疗(ART)且基线CD4>200个/μL的HIV感染者123605例,随访至12个月、脱失或死亡。诊断后≤30天启动ART者治疗脱失率6.72%、病毒学失败率5.45%,均低于延迟启动者;延迟治疗与脱失和病毒学失败风险升高相关。

要点

  • 诊断后≤30天启动ART者治疗脱失率6.72%,低于91-365天组的8.91%和>365天组的12.64%。
  • ≤30天组病毒学失败率5.45%,低于31-90天组的7.39%、91-365天组的9.64%和>365天组的12.67%。
  • 延迟启动ART与治疗脱失和病毒学失败风险升高相关。

核心结论

  • HIV诊断后30天内启动ART与治疗失败风险显著降低相关,凸显实施即检即治政策的必要性。

研究设计与样本

  • 全国队列研究,纳入2011年1月1日至2014年12月31日在中国启动ART且基线CD4结果>200个/μL的HIV感染者123605例,随访至12个月、脱失或死亡。
  • 采用Cox回归和log-binomial回归评估治疗脱失和病毒学失败(病毒载量≥400拷贝/mL)的决定因素。

主要发现

  • ≤30天组治疗脱失率为6.72%,91-365天组为8.91%,>365天组为12.64%,≤30天组显著更低。
  • ≤30天组病毒学失败率为5.45%,31-90天组为7.39%,91-365天组为9.64%,>365天组为12.67%,≤30天组显著更低。
  • 延迟治疗者治疗脱失风险升高:91-365天组aHR=1.33(95%CI 1.25-1.42),>365天组aHR=1.55(95%CI 1.47-1.54)。
  • 延迟治疗者病毒学失败风险升高:31-90天组aRR=1.35(95%CI 1.26-1.45),91-365天组aRR=1.66(95%CI 1.55-1.78),>365天组aRR=1.85(95%CI 1.74-1.97)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People living with human immunodeficiency virus (PLWH) are still being diagnosed late, rendering the benefits of "early" antiretroviral therapy (ART) unattainable. Therefore, we aimed to evaluate the benefits of "immediate" ART. METHODS: A nationwide cohort of PLWH in China who initiated ART January 1, 2011, to December 31, 2014 and had baseline CD4 results >200 cells/μL were censored at 12 months, dropout, or death, whichever came first. Treatment dropout and virological failure (viral load ≥400 copies/mL) were measured. Determinants were assessed by Cox and log-binomial regression. RESULTS: The cohort included 123605 PLWH. The ≤30 days group had a significantly lower treatment dropout rate of 6.72%, compared to 8.91% for the 91-365 days group and to 12.64% for the >365 days group. The ≤30 days group also had a significantly lower virological failure rate of 5.45% (31-90 days: 7.39%; 91-365 days: 9.64%; >365 days: 12.67%). Greater risk of dropout (91-365 days: adjusted hazard ratio [aHR] = 1.33, 95% confidence interval [CI] = 1.25-1.42; >365 days: aHR = 1.55, CI = 1.47-1.54), and virological failure (31-90 days: adjusted risk ratio [aRR] = 1.35, CI = 1.26-1.45; 91-365 days: aRR = 1.66, CI = 1.55-1.78; >365 days: aRR = 1.85, CI = 1.74-1.97) were observed for those who delayed treatment. CONCLUSIONS: ART within 30 days of HIV diagnosis was associated with significantly reduced risk of treatment failure, highlighting the need to implement test-and-immediately-treat policies.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Wu Z, McGoogan JM, et al. Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011-2015. Clin Infect Dis. 2019. PMID: 29771296. doi:10.1093/cid/ciy400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。